Sagimet Biosciences Inc (SGMT)
4.32
-0.13
(-2.92%)
USD |
NASDAQ |
May 03, 16:00
4.32
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Enterprise Value: 42.97M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 42.97M |
May 02, 2024 | 47.12M |
May 01, 2024 | 36.27M |
April 30, 2024 | 29.57M |
April 29, 2024 | 40.10M |
April 26, 2024 | 34.67M |
April 25, 2024 | 30.21M |
April 24, 2024 | 38.18M |
April 23, 2024 | 41.69M |
April 22, 2024 | 33.72M |
April 19, 2024 | 33.08M |
April 18, 2024 | 31.80M |
April 17, 2024 | 34.99M |
April 16, 2024 | 38.50M |
April 15, 2024 | 50.63M |
April 12, 2024 | 59.25M |
April 11, 2024 | 71.69M |
April 10, 2024 | 66.59M |
April 09, 2024 | 74.57M |
April 08, 2024 | 76.80M |
April 05, 2024 | 74.57M |
April 04, 2024 | 79.03M |
April 03, 2024 | 78.40M |
April 02, 2024 | 72.33M |
April 01, 2024 | 72.01M |
Date | Value |
---|---|
March 28, 2024 | 78.08M |
March 27, 2024 | 87.97M |
March 26, 2024 | 72.01M |
March 25, 2024 | 71.69M |
March 22, 2024 | 49.03M |
March 21, 2024 | 53.50M |
March 20, 2024 | 50.63M |
March 19, 2024 | 48.08M |
March 18, 2024 | 33.40M |
March 15, 2024 | 34.04M |
March 14, 2024 | 42.97M |
March 13, 2024 | 53.42M |
March 12, 2024 | 64.26M |
March 11, 2024 | 79.89M |
March 08, 2024 | 88.50M |
March 07, 2024 | 110.83M |
March 06, 2024 | 117.85M |
March 05, 2024 | 98.07M |
March 04, 2024 | 104.45M |
March 01, 2024 | 97.12M |
February 29, 2024 | 100.62M |
February 28, 2024 | 108.92M |
February 27, 2024 | 140.81M |
February 26, 2024 | 134.75M |
February 23, 2024 | 116.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-50.78M
Minimum
Nov 13 2023
342.49M
Maximum
Aug 03 2023
116.83M
Average
72.62M
Median
Oct 02 2023
Enterprise Value Benchmarks
Madrigal Pharmaceuticals Inc | 4.055B |
89bio Inc | 323.90M |
Viking Therapeutics Inc | 7.524B |
Akero Therapeutics Inc | 830.46M |
Arrowhead Pharmaceuticals Inc | 2.821B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -8.151M |
Total Expenses (Quarterly) | 9.466M |
EPS Diluted (Quarterly) | -0.356 |
Earnings Yield | -30.30% |